摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Chloro-N-thiophen-2-ylmethyl-benzamide | 332082-86-7

中文名称
——
中文别名
——
英文名称
4-Chloro-N-thiophen-2-ylmethyl-benzamide
英文别名
4-chloro-N-thiophen-2-ylmethylbenzamide;4-chloro-N-(thiophen-2-ylmethyl)benzamide
4-Chloro-N-thiophen-2-ylmethyl-benzamide化学式
CAS
332082-86-7
化学式
C12H10ClNOS
mdl
MFCD00098118
分子量
251.737
InChiKey
OPXTXCLTXQNTQH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    153-154 °C
  • 沸点:
    439.1±35.0 °C(Predicted)
  • 密度:
    1.311±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.083
  • 拓扑面积:
    57.3
  • 氢给体数:
    1
  • 氢受体数:
    2

SDS

SDS:8db4c40b4b3519f53512e6c0a252fcd9
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-Chloro-N-thiophen-2-ylmethyl-benzamide氯磺酸 作用下, 以 二氯甲烷 为溶剂, 以8.8 g (63%)的产率得到5-(4-氯苯胺甲基)噻吩-2-磺酰氯
    参考文献:
    名称:
    Pharmaceutically active sulfonamide derivatives
    摘要:
    本发明涉及公式I的磺酰胺衍生物,特别是用作药物活性化合物,以及含有这种磺酰胺衍生物的制药配方。所述磺酰胺衍生物是JNK途径的高效调节剂,特别是JNK2和3的高效且选择性抑制剂。本发明还涉及新型磺酰胺衍生物以及它们的制备方法。本发明中适合用作药物剂的公式I化合物是Ar1和Ar2分别独立于彼此的取代或未取代芳基或杂环芳基基团,X为O或S,优选为O;R1为氢或C1-C6烷基,优选为H,或R1与Ar1形成取代或未取代的5-6成员饱和或不饱和环;n为0到5的整数,优选为1-3,最优选为1。公式I中的Y是未取代或取代的4-12成员饱和环或双环烷基,其中至少有一个氮原子,该环中的一个氮原子与公式I中的磺酰基形成键合,从而提供磺酰胺。
    公开号:
    EP1088821A1
  • 作为产物:
    描述:
    2-噻吩甲胺4-氯苯甲酰氯N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 以98%的产率得到4-Chloro-N-thiophen-2-ylmethyl-benzamide
    参考文献:
    名称:
    Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
    摘要:
    本发明涉及具有亲脂基团并在生理条件下基本可溶的磺胺基衍生物。所述化合物特别适用作药用活性化合物。本发明还涉及含有这种磺胺基衍生物的药物配方。所述磺胺基衍生物是JNK途径的高效调节剂,特别是JNK 2和3的高效和选择性抑制剂。本发明还涉及新型磺胺基衍生物以及它们的制备方法。 根据本发明的式I化合物适用于药用剂的那些化合物是这样的: Ar1和Ar2分别独立地是取代或未取代的芳基或杂环芳基, X是O或S,优选为O; R1是氢或C1-C6烷基,或R1与Ar1形成取代或未取代的5-6元饱和或不饱和环; n是0到5的整数,优选为1-3之间,最优选为1; 式I中的Y是未取代或取代的4-12元饱和环或双环烷基,其上取代有至少一个可离子化基团,该基团连接有一个亲脂链,并且含有至少一个氮原子,其中所述环中的一个氮原子与式I的磺酰基形成键合,从而提供磺胺基。
    公开号:
    EP1193268A1
点击查看最新优质反应信息

文献信息

  • Pharmaceutically active sulfonyl hydrazide derivatives
    申请人:Applied Research Systems ARS Holding N.V.
    公开号:EP1088822A1
    公开(公告)日:2001-04-04
    The present invention is related to sulfonyl hydrazide derivatives according to formula I with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein Ar1 and Ar2 are independently from each other an unsubstituted or substituted aryl or heteroaryl group, X1 and X2 are independently from each other O or S; R1, R2, R3 are independently from each other hydrogen or a C1-C6-alkyl substituent or R1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1; or R2 and R3 form a substituted or unsubstituted 5-6-membered saturated or unsaturated ring; n is an integer from 0 to 5; G is selected from a group comprising or consisting of an unsubstituted or substituted 4-8-membered heterocycle containing at least one heteroatom, or G is a substituted or unsubstituted C1-C6-alkyl group; for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl hydrazide derivatives. Said sulfonyl hydrazide derivatives are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonyl hydrazide derivatives as well as to methods of their preparation.
    本发明涉及按照式I的磺酰基腙衍生物及其几何异构体,以对映体、二对映体的光学活性形式,以及它们的盐的药学上可接受的形式,其中Ar1和Ar2分别独立地是未取代或取代的芳基或杂环芳基,X1和X2分别独立地是O或S;R1、R2、R3分别独立地是氢或C1-C6-烷基取代基,或R1与Ar1形成取代或未取代的5-6元饱和或不饱和环;或R2和R3形成取代或未取代的5-6元饱和或不饱和环;n是0到5的整数;G选自包含或仅包含至少一个杂原子的未取代或取代的4-8元杂环的群,或G是取代或未取代的C1-C6烷基基团;用作药学活性化合物,以及含有这种磺酰基腙衍生物的制药配方。所述磺酰基腙衍生物是JNK途径的高效调节剂,特别是JNK 2和3的高效抑制剂。本发明还涉及新型磺酰基腙衍生物以及其制备方法。
  • Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
    申请人:Applied Research Systems ARS Holding N.V.
    公开号:EP1193268A1
    公开(公告)日:2002-04-03
    The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble under physiological conditions. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula I according to the present invention being suitable pharmaceutical agents are those wherein Ar1 and Ar2 are independently from each other substituted or unsubstituted aryl or heteroaryl groups, X is O or S, preferably O; R1 is hydrogen or a C1-C6-alkyl group, or R1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1; Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl which is substituted with at least one ionisable moiety to which a lipophilic chain is attached and which is containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide.ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide.
    本发明涉及具有亲脂基团并在生理条件下基本可溶的磺胺基衍生物。所述化合物特别适用作药用活性化合物。本发明还涉及含有这种磺胺基衍生物的药物配方。所述磺胺基衍生物是JNK途径的高效调节剂,特别是JNK 2和3的高效和选择性抑制剂。本发明还涉及新型磺胺基衍生物以及它们的制备方法。 根据本发明的式I化合物适用于药用剂的那些化合物是这样的: Ar1和Ar2分别独立地是取代或未取代的芳基或杂环芳基, X是O或S,优选为O; R1是氢或C1-C6烷基,或R1与Ar1形成取代或未取代的5-6元饱和或不饱和环; n是0到5的整数,优选为1-3之间,最优选为1; 式I中的Y是未取代或取代的4-12元饱和环或双环烷基,其上取代有至少一个可离子化基团,该基团连接有一个亲脂链,并且含有至少一个氮原子,其中所述环中的一个氮原子与式I的磺酰基形成键合,从而提供磺胺基。
  • Pharmaceutically active sulfonyl amino acid derivatives
    申请人:Applied Research Systems ARS Holding N.V.
    公开号:EP1088815A1
    公开(公告)日:2001-04-04
    The present invention is related to sulfonyl amino acid derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl amino acid derivatives. Said sulfonyl amino acid are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 33. The present invention is furthermore related to novel sulfonyl amino acid derivatives as well as to methods of their preparation.
    本发明涉及磺酰氨基酸衍生物,特别是用作药物活性化合物,以及含有此类磺酰氨基酸衍生物的制药配方。所述磺酰氨基酸是JNK途径的有效调节剂,它们特别是JNK 2和33的有效抑制剂。本发明还涉及新型磺酰氨基酸衍生物及其制备方法。
  • Pharmaceutically active sulfonamide derivatives
    申请人:Applied Research Systems ARS Holding N.V.
    公开号:EP1088821A1
    公开(公告)日:2001-04-04
    The present invention is related to sulfonamide derivatives of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula I according to the present invention being suitable pharmaceutical agents are those wherein Ar1 and Ar2 are independently from each other substituted or unsubstituted aryl or heteroaryl groups, X is O or S, preferably O; R1 is hydrogen or a C1-C6-alkyl group, preferably H, or R1 forms a substituted or unsubstituted 5-6-membered saturated or non-saturated ring with Ar1; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1. Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing the sulfonamide.
    本发明涉及公式I的磺酰胺衍生物,特别是用作药物活性化合物,以及含有这种磺酰胺衍生物的制药配方。所述磺酰胺衍生物是JNK途径的高效调节剂,特别是JNK2和3的高效且选择性抑制剂。本发明还涉及新型磺酰胺衍生物以及它们的制备方法。本发明中适合用作药物剂的公式I化合物是Ar1和Ar2分别独立于彼此的取代或未取代芳基或杂环芳基基团,X为O或S,优选为O;R1为氢或C1-C6烷基,优选为H,或R1与Ar1形成取代或未取代的5-6成员饱和或不饱和环;n为0到5的整数,优选为1-3,最优选为1。公式I中的Y是未取代或取代的4-12成员饱和环或双环烷基,其中至少有一个氮原子,该环中的一个氮原子与公式I中的磺酰基形成键合,从而提供磺酰胺。
  • [EN] PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES<br/>[FR] DERIVES SULFONAMIDES ACTIFS SUR LE PLAN PHARMACOLOGIQUE
    申请人:APPLIED RESEARCH SYSTEMS
    公开号:WO2001023378A1
    公开(公告)日:2001-04-05
    The present invention is related to sulfonamide derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula (I) according to the present invention being suitable pharmaceutical agents are those wherein Ar?1 and Ar2¿ are independently from each other substituted or unsubstituted aryl or heteroaryl groups, X is O or S, preferably O; R1 is hydrogen or a C¿1?-C6-alkyl group, or R?1¿ forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1; Y within formula (I) is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula (I) thus providing a sulfonamide.
    本发明涉及公式(I)的磺酰胺衍生物,特别是作为药物活性化合物的用途,以及包含这种磺酰胺衍生物的制药配方。所述的磺酰胺衍生物是JNK通路的有效调节因子,特别是JNK 2和3的有效且选择性抑制剂。本发明还涉及新的磺酰胺衍生物以及其制备方法。根据本发明的公式(I)化合物适合作为药物代理,其中Ar?1和Ar2¿是独立于彼此的取代或未取代的芳基或杂环芳基基团,X为O或S,优选为O; R1是氢或C¿1?-C6烷基,或R?1¿与Ar1形成取代或未取代的5-6成员饱和或不饱和环;n为0到5的整数,优选为1-3,最优选为1;公式(I)中的Y是未取代或取代的4-12成员饱和环或双环烷基,其中至少有一个氮原子,在该环内与公式(I)的磺酰基形成化学键,从而提供磺酰胺。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐